C-level executives and investors from across the healthcare industry rank pricing and reimbursement as the No. 1 strategic pressure facing the healthcare industry today, according to a survey from consulting firm Lazard.
Leaders said they expect value-based care and risk-sharing payment models to be the most transformative force in the healthcare industry over the next five to 10 years — 47 percent ranked this among the top three most transformative forces — beating out scientific innovation (38 percent).
The "Global Healthcare Leaders Study" polled 200 C-level executives and 100 investors from the U.S. and Europe, spanning three sectors of the healthcare industry: pharmaceutical and biotech, medical devices and technology, and healthcare services.
The survey revealed U.S. healthcare executives are more sensitive to the pricing and reimbursement challenges than their European peers, but perhaps slightly less convinced value-based care will be the solution. For example, 62 percent of U.S. healthcare executives ranked pricing pressure as a top concern, compared to 56 percent of European healthcare executives. Yet slightly more European executives polled — 49 percent — cited value-based care and risk-sharing models as a top transformative trend, compared to 41 percent of U.S. respondents.
Still, the majority of U.S. healthcare executives expect value-based care trends to continue in the years ahead. Fifty-five percent believe the majority of healthcare payments in the U.S. will be tied to value by 2020, according to the survey.
Read the full survey results here.